Loading
Cancer, Hypoxia, and Metabolism / Immune Cells in Cancer · Journal article
Experimental Hematology and Oncology · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical discovery study identifying SLC6A14 as a driver of immunosuppression and nutrient competition in pancreatic cancer, with STOCK1N-75990 as a candidate inhibitor showing anti-tumor activity and synergy with anti-PD1 therapy in animal models. The work is mechanistically sound and integrates multiple data types, but lacks human efficacy or safety evidence and remains at the stage of lead compound identification.
Integrated preclinical mechanistic study combining transcriptomic analysis, computational screening, in vitro experiments, and in vivo xenograft or syngeneic models. PDAC patient cohorts (transcriptomics and expression validation); in vitro dendritic cells and CD8⁺ T cells; in vivo PDAC tumor models in mice (specific model type not stated).. Intervention: STOCK1N-75990 (SLC6A14-specific inhibitor) administered as a pharmacological agent; genetic SLC6A14 knockdown or knockout (implied but not detailed); combination with anti-PD1 antibody.. Compared with: Standard in vivo and in vitro control conditions; anti-PD1 monotherapy in combination studies (specific control arm details not provided)..
SLC6A14 expression correlates with poor patient outcomes in clinical cohorts SLC6A14 impairs amino acid uptake in dendritic cells and CD8⁺ T cells, exerting immunosuppressive effects STOCK1N-75990, a specific SLC6A14 inhibitor, exhibits marked anti-tumor activity and limited toxicity in preclinical models
No human efficacy or safety data reported; STOCK1N-75990 is a lead compound, not a clinical candidate with established pharmacokinetics or toxicology in humans STOCK1N-75990, a specific SLC6A14 inhibitor, exhibits marked anti-tumor activity and limited toxicity in preclinical models
This work identifies a potential metabolic immunotherapy target for PDAC but remains preclinical. Clinicians should await Phase 1 or Phase 2 human studies before considering therapeutic relevance; the synergy with anti-PD1 therapy is a mechanistic observation that requires validation in clinical settings.
Preclinical mechanistic study with in vitro and in vivo experiments identifying a putative target and lead inhibitor, lacking clinical efficacy or safety data in humans.
As stated by the source record.
Quoted from the source exactly as published.
This work identifies a potential metabolic immunotherapy target for PDAC but remains preclinical. Clinicians should await Phase 1 or Phase 2 human studies before considering therapeutic relevance; the synergy with anti-PD1 therapy is a mechanistic observation that requires validation in clinical settings.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Pancreatic ductal adenocarcinoma (PDAC) exhibits an immunosuppressive and nutrient-deficient tumor microenvironment (TME), where solute carrier (SLC) transporters are critical in metabolic reprogramming and intercellular communication. However, the precise mechanisms by which specific SLCs contribute to therapeutic resistance through the TME remain unclear. We integrated transcriptomic data from clinical cohorts with computational analysis and expression validation to identify the SLC family members most closely linked to PDAC patient outcomes. Using in vitro and in vivo experiments along with multi‑omics approaches, we further clarified its functional roles in stromal–immune–metabolic networks within the TME. Following virtual screening of a million‑compound library and validated by binding assays, two target‑specific inhibitors were identified. Using pharmacological and genetic methods, the therapeutic potential of targeting this pathway was systematically evaluated. SLC6A14 is identified as a prognostic biomarker and functional driver of PDAC progression, with higher expression levels correlating with poor patient outcomes; it facilitates tumor growth by modifying amino acid metabolic reprogramming and exerting immunosuppressive effects by competitively impairing amino acid uptake in dendritic cells and CD8⁺ T cells. STOCK1N-75990 is a specific SLC6A14 inhibitor that competitively blocks amino acid binding, induces intracellular nutrient deprivation, and causes profound metabolic collapse; it exhibits marked anti-tumor activity and limited toxicity in preclinical models, synergizing with anti-PD1 therapy. These findings establish SLC6A14 as a potent multifunctional therapeutic target and demonstrate the clinical relevance of its inhibitors as a metabolic immunotherapy for PDAC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.